Findings from a prospective phase II study with dostarlimab for advanced local rectal cancer
In a prospective phase II study that involved patients with mismatch repair–deficient locally advanced rectal cancer, treatment with neoadjuvant single-agent, PD1 inhibitor dostarlimab resulted in a clinical complete response—as ...
Jun 9, 2022
0
72